查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2103052

肥胖相關癌症的流行病學分析與預測：2026-2035年

Obesity-Linked Cancer Epidemiology Analysis and Forecast, 2026-2035
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

肥胖是全球最重要的可控癌症危險因子之一。超重會導致慢性發炎、胰島素阻抗、荷爾蒙失衡、脂肪因子紊亂和代謝紊亂，所有這些都會增加患多種癌症的風險。流行病學證據證實，肥胖與多種癌症密切相關，包括乳癌、大腸癌、子宮內膜癌、肝癌、胰臟癌、腎臟癌和食道腺癌。隨著已開發國家和開發中國家肥胖率的上升，全球肥胖相關癌症的負擔日益加重，凸顯了進行全面流行病學分析的必要性。

流行病學分析能夠提供關於疾病盛行率、發病率、死亡率趨勢、危險因子分佈、患者人口統計特徵、肥胖相關癌症負擔以及長期醫療保健影響的關鍵資訊。製藥公司、醫療機構、公共衛生機構、研究機構和政策制定者越來越依賴流行病學數據來支持預防策略、資源分配、治療方案開發和醫療保健規劃。隨著肥胖成為嚴重的全球健康挑戰，流行病學資訊正成為癌症研究和疾病管理的重要組成部分。

市場促進因素

全球肥胖盛行率不斷上升

市場成長最重要的促進因素之一是全球肥胖率的持續上升。都市化、久坐的生活方式、不健康的飲食習慣以及體育鍛煉的減少，都導致了各個年齡層肥胖率的上升。

隨著肥胖率的上升，醫療保健系統中與肥胖相關的癌症發生率也相應增加。這一趨勢顯著提高了對流行病學監測和長期疾病負擔評估的需求。

肥胖相關癌症發生率增加

研究表明，肥胖與多種癌症密切相關。肥胖會增加停經後乳癌、大腸癌、子宮內膜癌、胰臟癌、肝癌、腎癌以及其他幾種惡性腫瘤的風險。

為了應對這些癌症發生率的上升，醫療和研究機構正在投資先進的流行病學研究和監測計畫。

擴大癌症監測計劃

各國政府和醫療機構正增加對癌症登記處、疾病監測網、人口健康資料庫和公共衛生監測計畫的投資。

這些項目將提高我們收集數據、追蹤疾病和評估風險的能力，使我們能夠更準確地評估與肥胖相關的癌症趨勢和未來的疾病負擔。

人們越來越關注預防醫學

醫療保健系統越來越重視預防性醫療模式。了解肥胖相關癌症的風險對於制定有效的預防方案、生活方式乾預措施、篩檢策略和公共衛生政策至關重要。

隨著預防腫瘤學的重要性日益凸顯，對流行病學分析和人口癌症資訊的需求也隨之增加。

本報告對全球肥胖相關癌症市場進行了流行病學概述，總結了疾病概況、流行病學促進因素和抑制因素、商業化和治療途徑、創新和臨床開發前景、按癌症類型和 BMI 分類等各種類別進行的流行病學預測、區域/主要國家趨勢、相關政策和法規、競爭格局、主要公司簡介以及以及展望。

目錄

第1章執行摘要

  • 肥胖相關癌症的流行病學：概述
  • 調查範圍和目標
  • 流行病學中的重要發現
  • 疾病負擔概述
  • 已確診和已治療患者人數的趨勢
  • 關鍵風險因素評估
  • 篩檢和早期檢測的趨勢
  • 治療途徑概述
  • 流行病學的未來展望
  • 從公共衛生角度來看，具有策略意義

第2章：疾病概論及流行病學分析

  • 肥胖相關癌症：概述
  • 肥胖相關癌症的分類
    • 乳癌
    • 結腸癌
    • 子宮內膜癌
    • 胰臟癌
    • 肝癌
    • 食道腺癌
    • 腎癌
    • 卵巢癌
    • 胃賁門癌
    • 膽囊癌
    • 甲狀腺癌
    • 多發性骨髓瘤
    • 腦膜瘤
  • 病理學和疾病機制
    • 肥胖引起的荷爾蒙失調
    • 高胰島素血症和IGF訊號傳導
    • 脂肪因子和細胞激素失衡
    • 氧化壓力和DNA損傷
    • 腸道菌叢變化與癌症風險
  • 流行病學概述
    • 全球發病率分析
    • 全球盛行率分析
    • 死亡率分析
    • 存活率評估
    • 肥胖盛行率與癌症疾病負擔之間的相關性
    • 基於BM​​I的風險分層
    • 年齡特異性流行病學
    • 性別流行病學
    • 都市區和農村地區的疾病負擔
    • 兒童和青少年肥胖症的趨勢
  • 流行病學：按癌症類型分類
    • 乳癌
    • 結腸癌
    • 子宮內膜癌
    • 肝癌
    • 胰臟癌
    • 腎癌
    • 其他與肥胖相關的癌症
  • 疾病負擔及其對醫療保健的影響

第3章：疾病的動態

  • 流行病學促進因素
    • 全球肥胖率不斷上升
    • 久坐生活方式的趨勢
    • 飲食習慣的改變和超加工食品的消費
    • 人口老化動態
    • METABOLIC INC.症候群的盛行率
  • 流行病學抑制因素
    • 早期癌症檢測的局限性
    • 高危險群意識薄弱
    • 篩檢機會差異
    • 發展中地區診斷不足
  • 公共衛生領域的機遇
    • 擴大肥胖預防計劃
    • 基於人群的癌症篩檢措施
    • 生活方式乾預計劃
    • 精準預防方法
    • 人工智慧驅動的風險預測模型
  • 疾病管理的挑戰
    • 合併症負擔
    • 肥胖患者治療的複雜性
    • 醫療基礎設施的限制
    • 長期監測面臨的挑戰

第4章 商業化與治療獲取

  • 獲得診斷和篩檢
    • 癌症篩檢趨勢
    • 取得診斷影像
    • 分子診斷實施現狀
    • 群體風險分層計劃
  • 治療可近性分析
    • 獲得外科癌症治療的機會
    • 獲得放射治療的機會
    • 獲得分子標靶治療的機會
    • 獲得免疫療法
    • 醫療基礎設施評估
  • 還款系統狀態
    • 公共償還系統
    • 私人保險的承保範圍
    • 癌症治療報銷的挑戰
    • 肥胖管理專案的福利覆蓋範圍

第5章：創新與臨床開發展望

  • 新創新趨勢
    • 精準腫瘤學的整合
    • 代謝生物標記的開發
    • 人工智慧在癌症風險評估的應用
    • 液態切片的介紹
    • 預防腫瘤學項目，重點在於肥胖
  • 按開發階段分類的管道概覽
    • 調查階段
    • 臨床前調查計畫
    • I期臨床試驗
    • 二期臨床試驗
    • III期臨床試驗
  • 按作用機制分類的管道
    • 免疫查核點抑制劑
    • 荷爾蒙療法
    • 分子標靶治療
    • 代謝途徑調節因子
    • 抗發炎治療方法
  • 臨床試驗現狀

第6章 當前治療狀況

  • 標準治療概述
    • 外科手術
    • 放射治療
    • 化療
    • 荷爾蒙療法
    • 免疫療法
    • 分子標靶治療
  • 已通過核准的抗癌藥物，常用於治療肥胖相關癌症
    • Pembrolizumab（Keytruda）：默克公司
    • Nivolumab（Opdivo）：百時美施貴寶
    • 曲妥珠單抗（赫賽汀）：羅氏
    • Bevacizumab（阿瓦斯汀）：羅氏
    • Lenvatinib（樂衛瑪）：衛材
    • Palbociclib（Ibrance）：輝瑞
    • 阿貝西利布（Verzenio）：禮來公司
    • Pembrolizumab+Lenvatinib聯合治療
    • Dostallimab（Jemperli）：GSK plc
    • Sorafenib（Nexavar）：拜耳
  • 治療指南摘要
    • NCCN指南
    • ESMO指南
    • ASCO指南
    • 世界衛生組織關於肥胖和癌症預防的建議
  • 新的治療趨勢
    • 個人化癌症治療方法
    • 將體重管理納入癌症治療
    • 基於免疫代謝的治療
    • 預防腫瘤策略

第7章 流行病學預測分析

  • 預測方法
  • 癌症類型特異性預測
    • 乳癌
    • 結腸癌
    • 子宮內膜癌
    • 肝癌
    • 胰臟癌
    • 腎癌
    • 其他與肥胖相關的惡性腫瘤
  • 基於人口的預測
    • 成人
    • 老年人
    • 兒童和青少年
    • 男性
    • 女士

第8章 流行病學細分

  • 按類型分類的癌症
    • 乳癌
    • 結腸癌
    • 子宮內膜癌
    • 胰臟癌
    • 肝癌
    • 腎癌
    • 食道腺癌
    • 卵巢癌
    • 甲狀腺癌
    • 多發性骨髓瘤
  • 按BMI分類
    • 超重
    • 第一級肥胖
    • 二級肥胖
    • 三級肥胖
  • 按年齡層
    • 兒童
    • 成人
    • 老年人
  • 按性別
    • 男人
    • 女士
  • 按診斷狀態
    • 已確診患者
    • 正在接受治療的患者
    • 未治療的患者

第9章 區域分析

  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
    • 肥胖症盛行率趨勢
    • 癌症疾病負擔評估
    • 篩檢和診斷挑戰
    • 治療途徑概述
    • 公共衛生基礎設施

第10章：主要國家分析

  • 加拿大
  • 德國
  • 中國
  • 日本
  • 印度

第11章 法規與政策概述

  • 美國
  • 歐洲
  • 日本
  • 印度
  • 中國
  • 全球公共衛生舉措

第12章 競爭格局

  • 流行病學研究生態系統
  • 策略聯盟
  • 臨床開發趨勢

第13章：公司簡介

  • F. Hoffmann-La Roche
  • Merck & Co.
  • Bristol Myers Squibb
  • AstraZeneca
  • Pfizer
  • Novartis
  • Johnson & Johnson
  • Gilead Sciences

第14章 未來展望

  • 未來流行病學趨勢
  • 新的公共衛生優先事項
  • 未來治療模式
  • 策略建議

第15章：調查方法

簡介目錄
Product Code: KSI-008848

Obesity has emerged as one of the most significant modifiable risk factors for cancer worldwide. Excess body weight contributes to chronic inflammation, insulin resistance, hormonal imbalances, adipokine dysregulation, and metabolic disturbances that increase the risk of multiple malignancies. Epidemiological evidence has established strong associations between obesity and several cancer types, including breast cancer, colorectal cancer, endometrial cancer, liver cancer, pancreatic cancer, kidney cancer, and esophageal adenocarcinoma. Growing obesity rates across both developed and developing economies are increasing the global burden of obesity-associated cancers and creating a greater need for comprehensive epidemiological analysis.

Epidemiology analysis provides critical insights into disease prevalence, incidence, mortality patterns, risk factor distribution, patient demographics, obesity-attributable cancer burden, and long-term healthcare impacts. Pharmaceutical companies, healthcare organizations, public health agencies, research institutions, and policymakers increasingly rely on epidemiological data to support prevention strategies, resource allocation, therapeutic development, and healthcare planning. As obesity continues to expand as a global health challenge, epidemiological intelligence is becoming an essential component of oncology research and disease management.

Market Drivers

Rising Global Obesity Prevalence

One of the most important drivers of market growth is the continued increase in obesity rates worldwide. Urbanization, sedentary lifestyles, unhealthy dietary patterns, and reduced physical activity are contributing to rising obesity prevalence across all age groups.

As obesity rates increase, healthcare systems are witnessing a corresponding rise in obesity-associated cancer incidence. This trend is generating substantial demand for epidemiological monitoring and long-term disease burden assessment.

Increasing Incidence of Obesity-Associated Cancers

Research has demonstrated strong links between obesity and multiple cancer types. Obesity contributes to increased risks of postmenopausal breast cancer, colorectal cancer, endometrial cancer, pancreatic cancer, liver cancer, kidney cancer, and several other malignancies.

The growing incidence of these cancers is encouraging healthcare organizations and research institutions to invest in advanced epidemiological studies and surveillance programs.

Expansion of Cancer Surveillance Programs

Governments and healthcare organizations are increasingly investing in cancer registries, disease surveillance networks, population health databases, and public health monitoring initiatives.

These programs improve data collection, disease tracking, and risk assessment capabilities, enabling more accurate evaluation of obesity-related cancer trends and future disease burden.

Growing Focus on Preventive Healthcare

Healthcare systems are placing greater emphasis on prevention-oriented healthcare models. Understanding obesity-attributable cancer risk is critical for designing effective prevention programs, lifestyle interventions, screening strategies, and public health policies.

The increasing importance of preventive oncology is strengthening demand for epidemiological analysis and population-level cancer intelligence.

Market Restraints

Variability in Data Collection Standards

Differences in healthcare infrastructure, cancer registry quality, obesity measurement methods, and reporting systems can create inconsistencies in epidemiological datasets.

Variations in data quality and collection practices may limit comparability across regions and affect the accuracy of global disease burden estimates.

Underreporting in Emerging Markets

Many developing countries continue to face challenges related to cancer diagnosis, disease registration, obesity monitoring, and healthcare access.

Limited surveillance infrastructure can result in underreporting of both obesity prevalence and obesity-associated cancer incidence, creating gaps in epidemiological assessments.

Complex Multifactorial Disease Relationships

Cancer development is influenced by numerous factors including genetics, environmental exposures, lifestyle behaviors, age, and socioeconomic conditions.

The complex interaction between obesity and other cancer risk factors can make it difficult to isolate obesity-specific contributions to disease incidence and outcomes.

Technology and Segment Insights

The global obesity-linked cancer epidemiology analysis market can be segmented by cancer type, risk factor category, demographic group, data source, application, end user, and geography.

By cancer type, the market includes breast cancer, colorectal cancer, endometrial cancer, liver cancer, pancreatic cancer, kidney cancer, esophageal adenocarcinoma, gallbladder cancer, ovarian cancer, thyroid cancer, and other obesity-associated malignancies. Breast, colorectal, and endometrial cancers represent major segments due to their well-established association with obesity and significant disease burden.

By risk factor category, the market includes obesity, overweight status, metabolic syndrome, insulin resistance, physical inactivity, dietary factors, and associated comorbidities such as diabetes and non-alcoholic fatty liver disease. Obesity remains the primary segment due to its direct role in cancer development and progression.

By demographic group, the market includes pediatric, adult, and geriatric populations, as well as gender-specific analyses. Adult and elderly populations account for a significant share due to the higher prevalence of both obesity and cancer among these groups.

By data source, the market includes cancer registries, electronic health records, hospital databases, insurance claims databases, public health surveillance systems, academic studies, and national health surveys. Cancer registries and population-based databases serve as critical sources for epidemiological analysis and disease tracking.

By application, the market includes prevalence analysis, incidence forecasting, mortality assessment, healthcare planning, risk stratification, prevention strategy development, clinical research support, and policy formulation. Disease burden assessment and preventive healthcare planning represent major application areas due to increasing focus on population health management.

By end user, the market serves pharmaceutical companies, biotechnology firms, healthcare providers, academic institutions, public health agencies, government organizations, contract research organizations, and healthcare consulting firms. Public health agencies and research institutions represent significant end-user groups because of their role in cancer surveillance and prevention initiatives.

Technological advancements are significantly enhancing epidemiological capabilities through artificial intelligence, machine learning, predictive analytics, genomics, digital health platforms, real-world evidence databases, and advanced population health modeling systems. These technologies improve disease forecasting, patient stratification, risk assessment, and healthcare planning efficiency.

The integration of obesity metrics, genomic information, lifestyle data, and cancer outcomes is enabling more sophisticated epidemiological models that support precision prevention strategies and targeted public health interventions.

Geographically, North America dominates the market due to high obesity prevalence, extensive cancer surveillance infrastructure, advanced healthcare systems, and strong investment in public health research. Europe maintains a substantial market position supported by comprehensive healthcare databases and cancer registries. Asia-Pacific is expected to experience significant growth owing to increasing obesity rates, expanding healthcare infrastructure, rising cancer incidence, and growing investments in epidemiological research. Latin America and the Middle East & Africa are gradually strengthening disease surveillance systems and cancer registry programs.

Competitive and Strategic Outlook

The competitive landscape includes epidemiology research organizations, healthcare analytics providers, academic institutions, public health agencies, contract research organizations, and specialized healthcare intelligence companies. Organizations are increasingly investing in advanced analytics platforms, real-world evidence systems, digital registries, and population health databases to improve epidemiological accuracy and forecasting capabilities.

Strategic collaborations between healthcare providers, academic institutions, government agencies, and research organizations are becoming increasingly common as stakeholders seek to improve data quality and expand understanding of obesity-associated cancer risks.

The growing emphasis on precision prevention, population health management, and evidence-based healthcare planning is expected to create new opportunities for organizations providing epidemiological intelligence and cancer burden analysis solutions. As healthcare systems increasingly prioritize prevention-focused oncology strategies, demand for obesity-linked cancer epidemiology data is expected to remain strong.

Conclusion

The global obesity-linked cancer epidemiology analysis market is poised for sustained growth through 2031, driven by rising obesity prevalence, increasing incidence of obesity-associated cancers, expanding cancer surveillance programs, and growing emphasis on preventive healthcare. Epidemiological intelligence is becoming increasingly important for understanding disease burden, identifying high-risk populations, supporting therapeutic development, and guiding public health policy. Although challenges related to data consistency, underreporting, and multifactorial disease interactions remain, ongoing advancements in analytics, digital health technologies, and population health research are expected to significantly strengthen the value and impact of obesity-linked cancer epidemiology analysis worldwide.

Key Benefits of this Report

  • Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
  • Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
  • Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
  • Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
  • Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

  • Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
  • Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
  • Competitive positioning, strategies, and market share evaluation, and trade analysis
  • Revenue growth and forecast assessment across segments and regions
  • Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Overview of Obesity-Linked Cancer Epidemiology
  • 1.2 Scope and Objectives of the Report
  • 1.3 Key Epidemiological Insights
  • 1.4 Disease Burden Overview
  • 1.5 Diagnosed and Treated Population Trends
  • 1.6 Key Risk Factor Assessment
  • 1.7 Screening and Early Detection Trends
  • 1.8 Treatment Access Overview
  • 1.9 Future Epidemiology Outlook
  • 1.10 Strategic Public Health Implications

2. Disease Overview & Epidemiology Analysis

  • 2.1 Introduction to Obesity-Linked Cancers
    • 2.1.1 Definition and Clinical Background
    • 2.1.2 Mechanistic Link Between Obesity and Cancer
    • 2.1.3 Adiposity-Driven Hormonal and Metabolic Alterations
    • 2.1.4 Chronic Inflammation and Tumorigenesis
    • 2.1.5 Obesity, Insulin Resistance, and Cancer Progression
  • 2.2 Classification of Obesity-Linked Cancers
    • 2.2.1 Breast Cancer
      • 2.2.1.1 Postmenopausal Breast Cancer
      • 2.2.1.2 Triple-Negative Breast Cancer
    • 2.2.2 Colorectal Cancer
    • 2.2.3 Endometrial Cancer
    • 2.2.4 Pancreatic Cancer
    • 2.2.5 Liver Cancer
    • 2.2.6 Esophageal Adenocarcinoma
    • 2.2.7 Kidney Cancer
    • 2.2.8 Ovarian Cancer
    • 2.2.9 Gastric Cardia Cancer
    • 2.2.10 Gallbladder Cancer
    • 2.2.11 Thyroid Cancer
    • 2.2.12 Multiple Myeloma
    • 2.2.13 Meningioma
  • 2.3 Pathophysiology and Disease Mechanism
    • 2.3.1 Obesity-Induced Hormonal Dysregulation
    • 2.3.2 Hyperinsulinemia and IGF Signaling
    • 2.3.3 Adipokines and Cytokine Imbalance
    • 2.3.4 Oxidative Stress and DNA Damage
    • 2.3.5 Gut Microbiome Alterations and Cancer Risk
  • 2.4 Epidemiology Overview
    • 2.4.1 Global Incidence Analysis
    • 2.4.2 Global Prevalence Analysis
    • 2.4.3 Mortality Analysis
    • 2.4.4 Survival Rate Assessment
    • 2.4.5 Obesity Prevalence vs Cancer Burden Correlation
    • 2.4.6 BMI-Based Risk Stratification
    • 2.4.7 Age-Wise Epidemiology
    • 2.4.8 Gender-Based Epidemiology
    • 2.4.9 Urban vs Rural Disease Burden
    • 2.4.10 Pediatric and Adolescent Obesity Trends
  • 2.5 Epidemiology by Cancer Type
    • 2.5.1 Breast Cancer Epidemiology
    • 2.5.2 Colorectal Cancer Epidemiology
    • 2.5.3 Endometrial Cancer Epidemiology
    • 2.5.4 Liver Cancer Epidemiology
    • 2.5.5 Pancreatic Cancer Epidemiology
    • 2.5.6 Kidney Cancer Epidemiology
    • 2.5.7 Other Obesity-Associated Malignancies
  • 2.6 Disease Burden and Healthcare Impact
    • 2.6.1 Hospitalization Trends
    • 2.6.2 Long-Term Care Burden
    • 2.6.3 Economic Burden Assessment
    • 2.6.4 Quality-of-Life Impact
    • 2.6.5 Productivity Loss Analysis

3. Disease Dynamics

  • 3.1 Epidemiological Drivers
    • 3.1.1 Rising Global Obesity Rates
    • 3.1.2 Sedentary Lifestyle Trends
    • 3.1.3 Dietary Transition and Ultra-Processed Food Consumption
    • 3.1.4 Aging Population Dynamics
    • 3.1.5 Metabolic Syndrome Prevalence
  • 3.2 Epidemiological Restraints
    • 3.2.1 Limited Early Cancer Detection
    • 3.2.2 Low Awareness in High-Risk Populations
    • 3.2.3 Screening Access Inequality
    • 3.2.4 Underdiagnosis in Developing Regions
  • 3.3 Public Health Opportunities
    • 3.3.1 Expansion of Obesity Prevention Programs
    • 3.3.2 Population-Based Cancer Screening Initiatives
    • 3.3.3 Lifestyle Intervention Programs
    • 3.3.4 Precision Prevention Approaches
    • 3.3.5 AI-Driven Risk Prediction Models
  • 3.4 Challenges in Disease Management
    • 3.4.1 Comorbidity Burden
    • 3.4.2 Treatment Complexity in Obese Patients
    • 3.4.3 Healthcare Infrastructure Limitations
    • 3.4.4 Long-Term Monitoring Challenges

4. Commercial & Treatment Access Landscape

  • 4.1 Diagnosis and Screening Access
    • 4.1.1 Cancer Screening Uptake Trends
    • 4.1.2 Access to Diagnostic Imaging
    • 4.1.3 Molecular Diagnostic Adoption
    • 4.1.4 Population Risk Stratification Programs
  • 4.2 Treatment Access Analysis
    • 4.2.1 Access to Surgical Oncology
    • 4.2.2 Access to Radiation Therapy
    • 4.2.3 Access to Targeted Therapy
    • 4.2.4 Access to Immunotherapy
    • 4.2.5 Healthcare Infrastructure Assessment
  • 4.3 Reimbursement Landscape
    • 4.3.1 Public Reimbursement Frameworks
    • 4.3.2 Private Insurance Coverage
    • 4.3.3 Reimbursement Challenges for Oncology Care
    • 4.3.4 Coverage for Obesity Management Programs

5. Innovation & Clinical Development Landscape

  • 5.1 Emerging Innovation Trends
    • 5.1.1 Precision Oncology Integration
    • 5.1.2 Metabolic Biomarker Development
    • 5.1.3 AI in Oncology Risk Assessment
    • 5.1.4 Liquid Biopsy Integration
    • 5.1.5 Obesity-Focused Preventive Oncology Programs
  • 5.2 Pipeline Landscape by Development Stage
    • 5.2.1 Discovery Stage Research
    • 5.2.2 Preclinical Research Programs
    • 5.2.3 Phase I Clinical Trials
    • 5.2.4 Phase II Clinical Trials
    • 5.2.5 Phase III Clinical Trials
  • 5.3 Pipeline Landscape by Mechanism of Action
    • 5.3.1 Immune Checkpoint Inhibitors
    • 5.3.2 Hormonal Therapies
    • 5.3.3 Targeted Therapies
    • 5.3.4 Metabolic Pathway Modulators
    • 5.3.5 Anti-Inflammatory Therapeutic Approaches
  • 5.4 Clinical Trial Landscape
    • 5.4.1 Obesity-Associated Oncology Trials
    • 5.4.2 Combination Therapy Studies
    • 5.4.3 Biomarker-Driven Trials
    • 5.4.4 Lifestyle Intervention Studies

6. Treatment Landscape

  • 6.1 Standard of Care Overview
    • 6.1.1 Surgery
    • 6.1.2 Radiation Therapy
    • 6.1.3 Chemotherapy
    • 6.1.4 Hormonal Therapy
    • 6.1.5 Immunotherapy
    • 6.1.6 Targeted Therapy
  • 6.2 Approved Oncology Therapies Commonly Used in Obesity-Linked Cancers
    • 6.2.1 Pembrolizumab (Keytruda) - Merck & Co.
    • 6.2.2 Nivolumab (Opdivo) - Bristol Myers Squibb
    • 6.2.3 Trastuzumab (Herceptin) - Roche
    • 6.2.4 Bevacizumab (Avastin) - Roche
    • 6.2.5 Lenvatinib (Lenvima) - Eisai
    • 6.2.6 Palbociclib (Ibrance) - Pfizer
    • 6.2.7 Abemaciclib (Verzenio) - Eli Lilly and Company
    • 6.2.8 Pembrolizumab + Lenvatinib Combination Regimens
    • 6.2.9 Dostarlimab (Jemperli) - GSK plc
    • 6.2.10 Sorafenib (Nexavar) - Bayer
  • 6.3 Treatment Guidelines Landscape
    • 6.3.1 NCCN Guidelines
    • 6.3.2 ESMO Guidelines
    • 6.3.3 ASCO Guidelines
    • 6.3.4 WHO Obesity and Cancer Prevention Recommendations
  • 6.4 Emerging Treatment Trends
    • 6.4.1 Personalized Oncology Approaches
    • 6.4.2 Weight Management Integration in Oncology
    • 6.4.3 Immunometabolism-Based Therapeutics
    • 6.4.4 Preventive Oncology Strategies

7. Epidemiology Forecast Analysis

  • 7.1 Forecast Methodology
    • 7.1.1 Historical Epidemiology Assessment
    • 7.1.2 Forecast Modeling Framework
    • 7.1.3 Risk Factor Correlation Analysis
  • 7.2 Forecast by Cancer Type
    • 7.2.1 Breast Cancer
    • 7.2.2 Colorectal Cancer
    • 7.2.3 Endometrial Cancer
    • 7.2.4 Liver Cancer
    • 7.2.5 Pancreatic Cancer
    • 7.2.6 Kidney Cancer
    • 7.2.7 Other Obesity-Linked Malignancies
  • 7.3 Forecast by Demographics
    • 7.3.1 Adult Population
    • 7.3.2 Geriatric Population
    • 7.3.3 Pediatric and Adolescent Population
    • 7.3.4 Male Population
    • 7.3.5 Female Population

8. Epidemiology Segmentation

  • 8.1 By Cancer Type
    • 8.1.1 Breast Cancer
    • 8.1.2 Colorectal Cancer
    • 8.1.3 Endometrial Cancer
    • 8.1.4 Pancreatic Cancer
    • 8.1.5 Liver Cancer
    • 8.1.6 Kidney Cancer
    • 8.1.7 Esophageal Adenocarcinoma
    • 8.1.8 Ovarian Cancer
    • 8.1.9 Thyroid Cancer
    • 8.1.10 Multiple Myeloma
  • 8.2 By BMI Classification
    • 8.2.1 Overweight
    • 8.2.2 Obesity Class I
    • 8.2.3 Obesity Class II
    • 8.2.4 Obesity Class III
  • 8.3 By Age Group
    • 8.3.1 Pediatric Population
    • 8.3.2 Adult Population
    • 8.3.3 Geriatric Population
  • 8.4 By Gender
    • 8.4.1 Male
    • 8.4.2 Female
  • 8.5 By Diagnosis Status
    • 8.5.1 Diagnosed Population
    • 8.5.2 Treated Population
    • 8.5.3 Untreated Population

9. Geographical Analysis

  • 9.1 North America
    • 9.1.1 Regional Obesity Burden
    • 9.1.2 Cancer Incidence Trends
    • 9.1.3 Screening and Diagnostic Access
    • 9.1.4 Treatment Accessibility
    • 9.1.5 Healthcare Infrastructure Assessment
  • 9.2 Europe
    • 9.2.1 Regional Epidemiology Trends
    • 9.2.2 Obesity-Driven Cancer Burden
    • 9.2.3 Public Health Initiatives
    • 9.2.4 Treatment Access Landscape
    • 9.2.5 Healthcare System Readiness
  • 9.3 Asia-Pacific
    • 9.3.1 Regional Obesity Trends
    • 9.3.2 Rising Cancer Incidence
    • 9.3.3 Healthcare Infrastructure Development
    • 9.3.4 Screening Adoption Trends
    • 9.3.5 Access Challenges
  • 9.4 Latin America
    • 9.4.1 Regional Epidemiology Burden
    • 9.4.2 Lifestyle Transition Impact
    • 9.4.3 Treatment Accessibility
    • 9.4.4 Public Health Response
    • 9.4.5 Healthcare Capacity Assessment
  • 9.5 Middle East & Africa
    • 9.5.1 Obesity Prevalence Trends
    • 9.5.2 Cancer Burden Assessment
    • 9.5.3 Screening and Diagnosis Challenges
    • 9.5.4 Treatment Access Overview
    • 9.5.5 Public Health Infrastructure

10. Key Countries Analysis

  • 10.1 United States
    • 10.1.1 Epidemiology Overview
    • 10.1.2 Obesity Prevalence Trends
    • 10.1.3 Screening Uptake
    • 10.1.4 FDA Regulatory Framework
    • 10.1.5 Treatment Access and Reimbursement
  • 10.2 Canada
    • 10.2.1 Epidemiology Overview
    • 10.2.2 Obesity Burden
    • 10.2.3 Screening Access
    • 10.2.4 Regulatory Framework
    • 10.2.5 Treatment Accessibility
  • 10.3 Germany
    • 10.3.1 Epidemiology Overview
    • 10.3.2 Obesity Trends
    • 10.3.3 Healthcare Infrastructure
    • 10.3.4 Regulatory Framework
    • 10.3.5 Reimbursement Landscape
  • 10.4 United Kingdom
    • 10.4.1 Epidemiology Overview
    • 10.4.2 Public Health Policies
    • 10.4.3 Screening Programs
    • 10.4.4 Regulatory Framework
    • 10.4.5 Treatment Access
  • 10.5 France
    • 10.5.1 Epidemiology Overview
    • 10.5.2 Obesity and Cancer Burden
    • 10.5.3 Healthcare Infrastructure
    • 10.5.4 Regulatory Framework
    • 10.5.5 Reimbursement Analysis
  • 10.6 Italy
    • 10.6.1 Epidemiology Overview
    • 10.6.2 Screening Trends
    • 10.6.3 Healthcare Access
    • 10.6.4 Regulatory Framework
    • 10.6.5 Treatment Accessibility
  • 10.7 Spain
    • 10.7.1 Epidemiology Overview
    • 10.7.2 Obesity Trends
    • 10.7.3 Public Health Initiatives
    • 10.7.4 Regulatory Framework
    • 10.7.5 Treatment Landscape
  • 10.8 China
    • 10.8.1 Epidemiology Overview
    • 10.8.2 Urbanization and Obesity Trends
    • 10.8.3 NMPA Regulatory Framework
    • 10.8.4 Screening Access
    • 10.8.5 Treatment Infrastructure
  • 10.9 Japan
    • 10.9.1 Epidemiology Overview
    • 10.9.2 Aging Population Impact
    • 10.9.3 PMDA Regulatory Framework
    • 10.9.4 Screening Programs
    • 10.9.5 Treatment Accessibility
  • 10.10 India
    • 10.10.1 Epidemiology Overview
    • 10.10.2 Rising Obesity Burden
    • 10.10.3 CDSCO Regulatory Framework
    • 10.10.4 Diagnostic Accessibility
    • 10.10.5 Treatment Access
  • 10.11 South Korea
    • 10.11.1 Epidemiology Overview
    • 10.11.2 Obesity Trends
    • 10.11.3 Healthcare Infrastructure
    • 10.11.4 Regulatory Framework
    • 10.11.5 Reimbursement Landscape
  • 10.12 Australia
    • 10.12.1 Epidemiology Overview
    • 10.12.2 Public Health Programs
    • 10.12.3 Screening Trends
    • 10.12.4 Regulatory Framework
    • 10.12.5 Treatment Access
  • 10.13 Brazil
    • 10.13.1 Epidemiology Overview
    • 10.13.2 Obesity Burden
    • 10.13.3 Healthcare Capacity
    • 10.13.4 Regulatory Framework
    • 10.13.5 Treatment Accessibility
  • 10.14 Mexico
    • 10.14.1 Epidemiology Overview
    • 10.14.2 Lifestyle Transition Impact
    • 10.14.3 Screening Access
    • 10.14.4 Regulatory Framework
    • 10.14.5 Reimbursement Analysis
  • 10.15 Saudi Arabia
    • 10.15.1 Epidemiology Overview
    • 10.15.2 Obesity Prevalence Trends
    • 10.15.3 Healthcare Infrastructure
    • 10.15.4 Regulatory Framework
    • 10.15.5 Treatment Access
  • 10.16 South Africa
    • 10.16.1 Epidemiology Overview
    • 10.16.2 Public Health Challenges
    • 10.16.3 Diagnostic Accessibility
    • 10.16.4 Regulatory Framework
    • 10.16.5 Treatment Landscape

11. Regulatory & Policy Landscape

  • 11.1 United States
    • 11.1.1 FDA Oncology Regulatory Framework
    • 11.1.2 Obesity Prevention Policies
    • 11.1.3 Cancer Screening Recommendations
  • 11.2 Europe
    • 11.2.1 EMA Oncology Regulations
    • 11.2.2 EU Public Health Policies
    • 11.2.3 Obesity Reduction Initiatives
  • 11.3 Japan
    • 11.3.1 PMDA Oncology Regulations
    • 11.3.2 National Obesity Management Policies
  • 11.4 India
    • 11.4.1 CDSCO Oncology Framework
    • 11.4.2 National Cancer Control Programs
  • 11.5 China
    • 11.5.1 NMPA Regulatory Environment
    • 11.5.2 Public Health and Obesity Policies
  • 11.6 Global Public Health Initiatives
    • 11.6.1 WHO Obesity Prevention Framework
    • 11.6.2 International Cancer Prevention Programs
    • 11.6.3 Population Screening Strategies

12. Competitive Landscape

  • 12.1 Epidemiology Research Ecosystem
    • 12.1.1 Academic Research Institutions
    • 12.1.2 Oncology Research Networks
    • 12.1.3 Public Health Organizations
  • 12.2 Strategic Collaborations
    • 12.2.1 Oncology Research Partnerships
    • 12.2.2 Diagnostic Collaborations
    • 12.2.3 Public-Private Partnerships
  • 12.3 Clinical Development Trends
    • 12.3.1 Immunotherapy Expansion
    • 12.3.2 Metabolic Oncology Research
    • 12.3.3 Biomarker-Based Clinical Programs

13. Company Profiles

  • 13.1 F. Hoffmann-La Roche
    • 13.1.1 Oncology Portfolio Overview
    • 13.1.2 Biomarker Integration Strategy
    • 13.1.3 Immuno-Oncology Programs
    • 13.1.4 Clinical Development Activities
  • 13.2 Merck & Co.
    • 13.2.1 Oncology Portfolio Overview
    • 13.2.2 Keytruda Expansion Strategy
    • 13.2.3 Precision Oncology Programs
    • 13.2.4 Clinical Trial Activities
  • 13.3 Bristol Myers Squibb
    • 13.3.1 Immuno-Oncology Leadership
    • 13.3.2 Cell Therapy Programs
    • 13.3.3 Clinical Development Activities
    • 13.3.4 Strategic Collaborations
  • 13.4 AstraZeneca
    • 13.4.1 Targeted Oncology Portfolio
    • 13.4.2 Lung Cancer Programs
    • 13.4.3 ADC Development Strategy
    • 13.4.4 Clinical Expansion Activities
  • 13.5 Pfizer
    • 13.5.1 Precision Oncology Portfolio
    • 13.5.2 Targeted Therapy Programs
    • 13.5.3 Global Clinical Expansion
    • 13.5.4 Biomarker Strategy
  • 13.6 Novartis
    • 13.6.1 Radioligand Therapy Programs
    • 13.6.2 Cell and Gene Therapy Activities
    • 13.6.3 Oncology Clinical Development
    • 13.6.4 Strategic Research Focus
  • 13.7 Johnson & Johnson
    • 13.7.1 Oncology Clinical Programs
    • 13.7.2 Combination Therapy Strategy
    • 13.7.3 Hematologic Oncology Focus
    • 13.7.4 Commercialization Approach
  • 13.8 Gilead Sciences
    • 13.8.1 Cell Therapy Programs
    • 13.8.2 ADC Clinical Development
    • 13.8.3 Manufacturing Expansion
    • 13.8.4 Oncology Research Strategy

14. Future Outlook

  • 14.1 Future Epidemiology Trends
    • 14.1.1 Global Obesity Burden Forecast
    • 14.1.2 Future Cancer Incidence Projection
    • 14.1.3 Early-Onset Cancer Trends
  • 14.2 Emerging Public Health Priorities
    • 14.2.1 Preventive Oncology Expansion
    • 14.2.2 Lifestyle Intervention Programs
    • 14.2.3 AI-Based Risk Prediction Integration
  • 14.3 Future Treatment Paradigm
    • 14.3.1 Precision Prevention Strategies
    • 14.3.2 Immunometabolism Research Expansion
    • 14.3.3 Personalized Oncology Approaches
  • 14.4 Strategic Recommendations
    • 14.4.1 Screening Expansion Priorities
    • 14.4.2 Healthcare Infrastructure Development
    • 14.4.3 Research Investment Priorities

15. Methodology

  • 15.1 Research Methodology
    • 15.1.1 Primary Research
    • 15.1.2 Secondary Research
    • 15.1.3 Expert Interviews
  • 15.2 Data Sources and Validation
    • 15.2.1 Epidemiology Databases
    • 15.2.2 Regulatory Databases
    • 15.2.3 Academic Publications
    • 15.2.4 Public Health Sources
  • 15.3 Forecasting Methodology
    • 15.3.1 Historical Trend Analysis
    • 15.3.2 Risk Correlation Modeling
    • 15.3.3 Population Projection Models
  • 15.4 Assumptions and Limitations
    • 15.4.1 Data Assumptions
    • 15.4.2 Research Constraints